Literature DB >> 12700295

Efficacy of methylprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson's disease.

Y Sato1, T Asoh, N Metoki, K Satoh.   

Abstract

BACKGROUND: Neuroleptic malignant syndrome (NMS) is a dangerous complication in patients with Parkinson's disease (PD). AIMS: To evaluate the efficacy of methylprednisolone pulse therapy compared to placebo in PD patients with NMS.
METHODS: In a double blind, placebo controlled study, 20 PD patients with NMS received steroid pulse therapy for three days, and 20 PD patients received placebo. Both groups received levodopa, bromocriptine, and dantrolene.
RESULTS: NMS in the steroid group healed within 10 days in 17 patients; median value of duration of illness of NMS in this group was 7 days (range 4-20). NMS in the placebo group healed within 10 days in five patients; in the remaining 15, it persisted for 12-27 days after the onset of NMS; median value of duration illness of NMS in this group was 18 days. Hyperthermia, rigidity, and consciousness improved within 10 days in many patients in the steroid group; these signs persisted more than 10 days in many patients in the placebo group.
CONCLUSIONS: Steroid pulse therapy is useful in NMS for reducing the illness duration and improving symptoms.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12700295      PMCID: PMC1738449          DOI: 10.1136/jnnp.74.5.574

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  8 in total

1.  Search for the presence of glucocorticoid receptors in dopaminergic neurons of rat ventral tegmental area and substantia nigra.

Authors:  A Czyrak; A Chocyk
Journal:  Pol J Pharmacol       Date:  2001 Nov-Dec

2.  Efficacy of prolonged large-dose dantrolene for severe neuroleptic malignant syndrome.

Authors:  S Tsujimoto; K Maeda; T Sugiyama; A Yokochi; H Chikusa; K Maruyama
Journal:  Anesth Analg       Date:  1998-05       Impact factor: 5.108

3.  Intravenous injection of levodopa is more effective than dantrolene as therapy for neuroleptic malignant syndrome.

Authors:  K Nisijima; M Noguti; T Ishiguro
Journal:  Biol Psychiatry       Date:  1997-04-15       Impact factor: 13.382

Review 4.  Neuroleptic malignant syndrome. Review of response to therapy.

Authors:  M R Rosenberg; M Green
Journal:  Arch Intern Med       Date:  1989-09

5.  Glucocorticoids have state-dependent stimulant effects on the mesencephalic dopaminergic transmission.

Authors:  P V Piazza; F Rougé-Pont; V Deroche; S Maccari; H Simon; M Le Moal
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-06       Impact factor: 11.205

6.  Levodopa withdrawal syndrome identical to neuroleptic malignant syndrome.

Authors:  W R Gibb; D N Griffith
Journal:  Postgrad Med J       Date:  1986-01       Impact factor: 2.401

7.  Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade?

Authors:  V W Henderson; G F Wooten
Journal:  Neurology       Date:  1981-02       Impact factor: 9.910

8.  The treatment of neuroleptic malignant syndrome using dantrolene sodium.

Authors:  Y Tsutsumi; K Yamamoto; S Matsuura; S Hata; M Sakai; K Shirakura
Journal:  Psychiatry Clin Neurosci       Date:  1998-08       Impact factor: 5.188

  8 in total
  10 in total

Review 1.  Treatment of movement disorder emergencies.

Authors:  Steven J Frucht
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 2.  Movement disorder emergencies.

Authors:  Steven J Frucht
Journal:  Curr Neurol Neurosci Rep       Date:  2005-07       Impact factor: 5.081

Review 3.  Movement disorder emergencies.

Authors:  Kathleen L Poston; Steven J Frucht
Journal:  J Neurol       Date:  2008-08       Impact factor: 4.849

4.  Neuroleptic malignant syndrome as a presenting feature of subacute sclerosing panencephalitis.

Authors:  Divyani Garg; Varun Reddy; Rajesh Kumar Singh; Deepa Dash; Rohit Bhatia; Manjari Tripathi
Journal:  J Neurovirol       Date:  2017-12-14       Impact factor: 2.643

Review 5.  The parkinsonism-hyperpyrexia syndrome.

Authors:  Edward J Newman; Donald G Grosset; Peter G E Kennedy
Journal:  Neurocrit Care       Date:  2008-08-20       Impact factor: 3.210

Review 6.  Bench-to-bedside review: Rhabdomyolysis -- an overview for clinicians.

Authors:  Ana L Huerta-Alardín; Joseph Varon; Paul E Marik
Journal:  Crit Care       Date:  2004-10-20       Impact factor: 9.097

7.  Neuroleptic Malignant Syndrome Associated with Refractory Acute Disseminated Encephalomyelitis.

Authors:  Silvia R Delgado; Leticia Tornes; Janice Maldonado; Jeffrey Hernandez; Yesica Campos; Kottil Rammohan
Journal:  Case Rep Neurol       Date:  2016-04-28

8.  Critical Illness Neuromyopathy Complicating Akinetic Crisis in Parkinsonism: Report of 3 Cases.

Authors:  Margherita Capasso; Maria Vittoria De Angelis; Antonio Di Muzio; Francesca Anzellotti; Laura Bonanni; Astrid Thomas; Marco Onofrj
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

9.  An unwell patient with Parkinson's disease: Hyperpyrexia syndrome in a heatwave.

Authors:  Elizabeth Mooney; Matthew D Smith; Emily J Henderson
Journal:  JRSM Open       Date:  2022-08-09

10.  Malignant syndrome in Parkinson's disease without dopaminergic drug withdrawal.

Authors:  C J Suresh Chandran
Journal:  Ann Indian Acad Neurol       Date:  2008-10       Impact factor: 1.383

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.